CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Gyre Therapeutics Inc - GYRE CFD

16.0992
31.05%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.1516
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Gyre Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 23.3492
Open* 24.5992
1-Year Change* 4388.09%
Day's Range* 16.0992 - 24.5992
52 wk Range 2.83-17.41
Average Volume (10 days) 90.13K
Average Volume (3 months) 769.23K
Market Cap 32.23M
P/E Ratio -100.00K
Shares Outstanding 2.53M
Revenue N/A
EPS -20.60
Dividend (Yield %) N/A
Beta 1.29
Next Earnings Date Mar 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 23.3492 1.1300 5.09% 22.2192 25.0292 21.6992
Nov 30, 2023 23.3092 -2.5900 -10.00% 25.8992 25.8992 21.3292
Nov 29, 2023 26.0892 0.3400 1.32% 25.7492 26.8992 24.0092
Nov 28, 2023 24.0092 3.0000 14.28% 21.0092 26.2992 21.0092
Nov 27, 2023 20.8192 1.3200 6.77% 19.4992 20.8992 17.5292
Nov 24, 2023 19.0392 1.8300 10.63% 17.2092 19.8992 17.2092
Nov 22, 2023 16.0992 2.8600 21.60% 13.2392 16.4092 13.2392
Nov 21, 2023 12.4792 -1.7200 -12.11% 14.1992 14.1992 11.7992
Nov 20, 2023 14.4992 -1.1000 -7.05% 15.5992 17.2992 14.2692
Nov 17, 2023 14.4092 1.4100 10.85% 12.9992 14.4992 12.9992
Nov 16, 2023 12.8192 0.2200 1.75% 12.5992 13.7192 12.5992
Nov 15, 2023 12.1492 2.6500 27.90% 9.4992 12.6592 9.4992
Nov 14, 2023 9.2892 0.2000 2.20% 9.0892 9.4792 8.9592
Nov 13, 2023 8.8592 0.0500 0.57% 8.8092 9.0992 8.6992
Nov 10, 2023 8.6992 -0.4200 -4.61% 9.1192 9.1992 8.2992
Nov 9, 2023 8.6692 -0.8400 -8.83% 9.5092 10.2492 8.4992
Nov 8, 2023 9.1992 1.0100 12.33% 8.1892 9.2492 8.0992
Nov 7, 2023 8.0492 0.6900 9.38% 7.3592 8.0992 7.3592
Nov 6, 2023 7.1592 0.4100 6.07% 6.7492 7.3292 6.7492
Nov 3, 2023 6.4392 0.0700 1.10% 6.3692 6.5192 6.3192

Gyre Therapeutics Inc Events

Time (UTC) Country Event
Thursday, March 28, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2023 Catalyst Biosciences Inc Earnings Release
Q4 2023 Catalyst Biosciences Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0.794 7.338 20.948 0 0.006
Revenue 0.794 7.338 20.948 0 0.006
Total Operating Expense 9.225 95.232 78.318 57.277 33.828
Selling/General/Admin. Expenses, Total 16.966 18.963 16.18 13.418 12.354
Research & Development 12.437 68.889 52.175 43.859 21.474
Operating Income -8.431 -87.894 -57.37 -57.277 -33.822
Interest Income (Expense), Net Non-Operating 0.537 0.039 0.561 2.145 2.233
Gain (Loss) on Sale of Assets 0 -0.116
Net Income Before Taxes -7.894 -87.933 -56.241 -55.178 -30.055
Net Income After Taxes -8.242 -87.933 -56.241 -55.178 -30.055
Net Income Before Extra. Items -8.242 -87.933 -56.241 -55.178 -30.055
Net Income -8.242 -87.933 -56.241 -55.178 -30.055
Income Available to Common Excl. Extra. Items -8.242 -87.933 -56.241 -55.178 -30.055
Income Available to Common Incl. Extra. Items -8.242 -87.933 -56.241 -55.178 -30.055
Diluted Net Income -8.242 -87.933 -56.241 -55.178 -30.055
Diluted Weighted Average Shares 31.5457 30.641 19.1793 12.0045 11.2139
Diluted EPS Excluding Extraordinary Items -0.26127 -2.86978 -2.93238 -4.59645 -2.68016
Diluted Normalized EPS -0.30083 -2.86978 -2.89067 -4.59645 -2.66982
Total Extraordinary Items
Total Adjustments to Net Income 0
Other, Net 0 -0.078 0.568 -0.046 1.65
Cost of Revenue, Total 0.798 7.38 9.163
Gross Profit -0.004 -0.042 11.785
Unusual Expense (Income) -20.976 0.8
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Cost of Revenue, Total 0 0 0 0 0
Gross Profit 0 0 0 0 0
Total Operating Expense 1.623 2.543 -0.178 40.274 5.166
Selling/General/Admin. Expenses, Total 2.408 2.225 3.97 4.165 4.363
Research & Development 0.415 0.318 0.588 0.66 0.803
Operating Income -1.623 -2.543 0.178 -40.274 -5.166
Interest Income (Expense), Net Non-Operating 0.047 0.073 0.096 0.167 0.283
Other, Net 0.001 -0.001
Net Income Before Taxes -1.576 -2.47 0.274 -40.106 -4.884
Net Income After Taxes -1.576 -2.472 0.26 -40.454 -4.884
Net Income Before Extra. Items -1.576 -2.472 0.26 -40.454 -4.884
Net Income -1.576 -2.472 0.26 -40.454 -4.884
Income Available to Common Excl. Extra. Items -1.576 -2.472 0.26 -40.454 -4.884
Income Available to Common Incl. Extra. Items -1.576 -2.472 0.26 -40.454 -4.884
Diluted Net Income -1.576 -2.472 0.26 -40.454 -4.884
Diluted Weighted Average Shares 37.9768 37.8001 37.9843 31.7649 31.4845
Diluted EPS Excluding Extraordinary Items -0.0415 -0.0654 0.00684 -1.27354 -0.15512
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.0415 -0.0654 -0.0742 -0.15821 -0.15512
Unusual Expense (Income) 0 0 -4.736 35.449 0
Other Operating Expenses, Total -1.2
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 28.206 51.476 89.51 96.066 123.991
Cash and Short Term Investments 21.666 46.851 79.354 76.865 120.127
Cash & Equivalents 21.666 44.347 30.36 15.369 31.213
Short Term Investments 0 2.504 48.994 61.496 88.914
Total Receivables, Net 5 1.818 3.313 15
Accounts Receivable - Trade, Net 5 1.818 3.313 15
Prepaid Expenses 1.54 2.807 6.843 4.201 3.814
Other Current Assets, Total 0 0.05
Total Assets 28.444 55.662 94.846 98.554 124.92
Property/Plant/Equipment, Total - Net 0.07 3.714 2.265 2.231 0.386
Property/Plant/Equipment, Total - Gross 0.671
Accumulated Depreciation, Total -0.285
Other Long Term Assets, Total 0.168 0.472 0.528 0.257 0.543
Total Current Liabilities 16.824 14.165 17.796 28.899 4.801
Accounts Payable 0.194 6.419 5.931 4.279 1.248
Accrued Expenses 4.072 7.516 9.882 9.62 3.538
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 12.558 0.23 1.983 15 0.015
Total Liabilities 16.824 14.573 18.777 30.218 4.975
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0 0.408 0.981 1.319 0.174
Total Equity 11.62 41.089 76.069 68.336 119.945
Common Stock 0.037 0.031 0.022 0.012 0.012
Additional Paid-In Capital 389.21 443.752 390.803 326.81 323.279
Retained Earnings (Accumulated Deficit) -410.936 -402.694 -314.761 -258.52 -203.342
Other Equity, Total 0 0.005 0.034 -0.004
Total Liabilities & Shareholders’ Equity 28.444 55.662 94.846 98.554 124.92
Total Common Shares Outstanding 2.51723 2.09409 1.47326 0.80276 0.79701
Redeemable Preferred Stock 33.309 0
Total Preferred Shares Outstanding 0 0
Long Term Investments 0 2.543
Preferred Stock - Non Redeemable, Net 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 5.132 7.62 14.014 28.206 30.246
Cash and Short Term Investments 2.228 6.923 8.099 21.666 23.09
Cash & Equivalents 2.228 6.923 8.099 21.666 23.09
Short Term Investments 0 0
Total Receivables, Net 1.2 0 5 5 5
Accounts Receivable - Trade, Net 0 0 5 5 5
Prepaid Expenses 1.704 0.697 0.915 1.54 2.156
Total Assets 9.964 12.394 18.75 28.444 31.019
Property/Plant/Equipment, Total - Net 0 0 0.018 0.07 0.605
Other Long Term Assets, Total 0.168 0.168 0.168 0.168 0.168
Total Current Liabilities 1.783 2.793 6.844 16.824 1.644
Accounts Payable 0.158 0.005 0.016 0.194 0.041
Accrued Expenses 1.625 2.788 1.828 4.072 1.603
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0 5 12.558 0
Total Liabilities 6.447 7.399 11.394 16.824 1.644
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 4.664 4.606 4.55 0 0
Total Equity 3.517 4.995 7.356 11.62 29.375
Common Stock 0.037 0.037 0.037 0.037 0.031
Additional Paid-In Capital 384.895 384.797 384.686 389.21 399.826
Retained Earnings (Accumulated Deficit) -414.724 -413.148 -410.676 -410.936 -370.482
Other Equity, Total
Total Liabilities & Shareholders’ Equity 9.964 12.394 18.75 28.444 31.019
Total Common Shares Outstanding 2.532 2.53179 2.51745 2.51723 2.09944
Long Term Investments
Preferred Stock - Non Redeemable, Net 0
Redeemable Preferred Stock 33.309 33.309 33.309 33.309
Note Receivable - Long Term 4.664 4.606 4.55
Total Preferred Shares Outstanding 0.01234 0.01234
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -8.242 -87.933 -56.241 -55.178 -30.055
Cash From Operating Activities -33.096 -83.755 -55.048 -43.613 -28.553
Cash From Operating Activities 0.23 0.29 0.138 0.146 0.149
Non-Cash Items -20.139 3.405 3.627 3.204 2.722
Changes in Working Capital -4.945 0.483 -2.572 8.215 -1.369
Cash From Investing Activities 55.426 48.189 9.663 27.392 -71.321
Capital Expenditures 0 -0.839 -0.267 -0.064 -0.376
Other Investing Cash Flow Items, Total 55.426 49.028 9.93 27.456 -70.945
Cash From Financing Activities -45.011 49.553 60.376 0.327 111.332
Issuance (Retirement) of Stock, Net 0.02 49.553 60.376 0.327 116.414
Issuance (Retirement) of Debt, Net 0 -5.082
Net Change in Cash -22.681 13.987 14.991 -15.894 11.458
Total Cash Dividends Paid -45.031
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 0.26 -8.242 32.212 37.096 -14.536
Cash From Operating Activities -6.216 -33.096 -31.621 -24.344 -12.05
Cash From Operating Activities 0.003 0.23 0.22 0.18 0.113
Non-Cash Items -4.526 -20.139 -55.85 -56.184 0.715
Changes in Working Capital -1.953 -4.945 -8.203 -5.436 1.658
Cash From Investing Activities 0.411 55.426 55.375 55.375 2.504
Other Investing Cash Flow Items, Total 0.411 55.426 55.375 55.375 2.504
Cash From Financing Activities -7.762 -45.011 -45.011 0.016 0.016
Issuance (Retirement) of Stock, Net 0.002 0.02 0.02 0.016 0.016
Net Change in Cash -13.567 -22.681 -21.257 31.047 -9.53
Capital Expenditures 0 0 0
Total Cash Dividends Paid -7.764 -45.031 -45.031

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Catalyst Biosciences, Inc. Company profile

About Catalyst Biosciences Inc

Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Catalyst Biosciences Inc revenues decreased 74% to $4.9M. Net loss increased 81% to $67.6M. Revenues reflect License decrease from $15.1M to $0K. Higher net loss reflects Research and development increase of 3% to $38.3M (expense), General and administrative - Balancing v increase of 9% to $11.3M (expense), Miscellaneous income (expense) decrease of 99% to $8K (income).

Equity composition

Common Stock $.001 Par, 04/11, 100M auth., 29,021,460 issd., Insiders control approx. 0.08%. IPO: 4/06 5,000,000 shs. @ $9per share by Deutsche Bank Securities. 8/15, 1-for-7 reverse stock split.

Industry: Biotechnology & Medical Research (NEC)

12770 High Bluff Drive, Suite 150
SAN DIEGO
CALIFORNIA 92130
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

Oil - Crude

73.37 Price
-1.470% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee -0.0019%
Overnight fee time 22:00 (UTC)
Spread 0.040

BTC/USD

41,800.65 Price
+5.080% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,034.27 Price
-1.820% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee 0.0118%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.62 Price
-0.680% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading